Learn about Research & Clinical Trials

Clinical Trial Finder

A Study to Test Whether BI 1839100 Improves Cough in People With Idiopathic Pulmonary Fibrosis or Progressive Pulmonary Fibrosis

Study Purpose

Adults 40 years of age and older with idiopathic pulmonary fibrosis (IPF) or 18 years and older with progressive pulmonary fibrosis (PPF) can participate in this study. Only people who have a chronic cough can take part. The purpose of this study is to find out how well BI 1839100 helps reduce coughing in people with IPF or PPF. Participants who have IPF are put into 4 groups by chance. Participants in 3 groups get different doses of BI 1839100. Participants in 1 group get placebo. Placebo looks like BI 1839100 but does not contain any medicine. Participants take the treatment for 3 months. After 1 month of treatment, participants who take the highest dose will have coughing measured to find out if the medicine works. If it does not work, the study may be stopped. Participants who have IPF are in the study for slightly longer than 4 months. During this time, they visit the study site 7 times. This study will also measure the effects of BI 1839100 on coughing and lung function in a smaller group of people with PPF. During the study, coughing is measured over 24 hours about once per month using a portable device given to participants to use during the study. Participants fill in questionnaires about their coughing. Doctors also perform breathing tests that measure how well the lungs are working at the site visits. Researchers compare the results between participants who take BI 1839100 and placebo. The doctors also regularly check participants' health and take note of any unwanted effects.

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

 No
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

 Interventional
Eligible Ages 18 Years and Over
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria. For Idiopathic Pulmonary Fibrosis (IPF) cohort:

  • - Minimum age: 40 years.
  • - Diagnosis of IPF.
  • - Chronic cough (>8 weeks prior to Visit 1) attributed to IPF and refractory to treatment for known causes (Principal Investigator (PI) assessment) - Cough Severity visual analogue scale (VAS) ≥30 mm at Visit 1 and Visit 2B.
  • - Forced vital capacity (FVC) ≥45% of predicted normal at Visit 1.
  • - Diffusing capacity of the lungs for carbon monoxide (DLCO) >25% of predicted normal at Visit 1.
  • - Patients may be either: - On stable therapy with nintedanib or pirfenidone for ≥12 weeks prior to Visit 1 and are planning to stay on this background treatment for the whole trial duration.
Combination of nintedanib plus pirfenidone will not be allowed.
  • - Not on therapy with nintedanib or pirfenidone for ≥12 weeks prior to Visit 1 (either antifibrotic (AF)-treatment naïve or previously discontinued) and do not plan to start or re-start AF treatment during the trial.
  • - Patients aged ≥40 years when signing the informed consent.
For Progressive Pulmonary Fibrosis (PPF) cohort:
  • - Minimum age: 18 years.
  • - Diagnosis of PPF.
  • - Chronic cough (>8 weeks prior to Visit 1) attributed to PPF, refractory to treatment for known causes (PI assessment) - Cough Severity VAS ≥30 mm at Visit 1 and Visit 2B.
  • - FVC ≥45% of predicted normal at Visit 1.
  • - DLCO ≥25% of predicted normal at Visit 1.
  • - If receiving immunomodulatory therapy for interstitial lung disease (ILD), allowed medications include tacrolimus, mycophenolate mofetil, or azathioprine (stable dose for 12 weeks prior to Visit 1) - Patients may be either: - On a stable therapy with nintedanib for ≥12 weeks prior to Visit 1 and are planning to stay on this background treatment for the whole trial duration.
  • - Not on a therapy with nintedanib for ≥12 weeks prior to Visit 1 (either AF-treatment naïve or previously discontinued) and do not plan to start or re-start AF treatment during the trial.
  • - Patients aged >18 years when signing the informed consent.
Further inclusion criteria apply. Exclusion criteria for IPF and PPF cohorts:
  • - Acute exacerbation of IPF/PPF within 12 weeks prior to Visit 1.
  • - Forced expiratory volume in 1 second (Forced expiratory volume in 1 second (FEV1))/FVC <0.7 at Visit 1.
  • - Known reversible airflow obstruction/response to bronchodilators.
  • - In the opinion of the Investigator, other clinically significant pulmonary abnormalities, including primary bronchitic and bronchiectatic disorder.
  • - Upper or lower respiratory tract infection within 4 weeks prior to Visit 1.
  • - Ongoing chronic pulmonary infection (e.g. mycobacterial or fungal disease) - Current smokers (tobacco use within the 6 months prior to Visit 1) - Initiation or change in supplemental oxygen requirement during 4 weeks prior to Visit 1 Further exclusion criteria apply.

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

 NCT06360094
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

 Phase 2
Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

 Boehringer Ingelheim
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

 N/A
Principal Investigator Affiliation N/A
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

 Industry
Overall Status Not yet recruiting
Countries
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

 Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
Study Website: View Trial Website
Arms & Interventions

Arms

Placebo Comparator: Phase IIa/IIb, IPF cohort: Placebo

Experimental: Phase IIa/IIb, IPF cohort: BI 1839100 low dose

Experimental: Phase IIa/IIb, IPF cohort: BI 1839100 medium dose

Experimental: Phase IIa/IIb, IPF cohort: BI 1839100 high dose

Placebo Comparator: Phase IIb, PPF cohort: Placebo

Experimental: Phase IIb, PPF cohort: BI 1839100 high dose

Interventions

Drug: - BI 1839100

BI 1839100

Drug: - Placebo

Placebo

Contact Information

This trial has no sites locations listed at this time. If you are interested in learning more, you can contact the trial's primary contact:

Boehringer Ingelheim

clintriage.rdg@boehringer-ingelheim.com

1-800-243-0127

For additional contact information, you can also visit the trial on clinicaltrials.gov.

Powered By